THOMAS JEFFERSON UNIVERSITY

No reported sub-awards as a subcontractor.

• IDT BIOLOGIKA GMBH

  UEI E14GD5J873N9 · not in the directory yet

  $8.3M

  Subcontracted by this company · 1 sub-award · latest May 21, 2025

  • National Institutes of Health
  • “BASE PERIOD � IMMUNOGENICITY AND PRIMARY PLATFORM DEVELOPMENT RABIES VIRUS BASED PLATFORM VACCINES. RABV CONSTRUCTS (FILORAB 1-3) EXPRESSING EBOV GP, SUDV GP OR MARV GP HAVE BEEN RECOVERED, CLONE PURIFIED AND MASTER VIRUS SEED (MVS) HAVE BEEN PREPARED.. THE GENE ENCODING LASV GPC HAS BEEN CLONED, INSERTED INTO THE RABV VECTOR AND SUCCESSFULLY RECOVERED IN VERO CELLS. CONTRACTOR SHALL CHARACTERIZE THE CDNA CLONES AND SHALL SEND TO SUBCONTRACTOR FOR GMP PRODUCTION OF MASTER SEED VIRUSES. THE CONTRACTOR SHALL PREPARE, INACTIVATE AND PURIFY FILORAB1 - 3 AND LASSARAB AT RESEARCH SCALE. CONTRACTOR SHALL USE THE PRODUCED VIRAL STOCKS FOR THE NHP IMMUNOGENICITY STUDIES. THE CONTRACTOR SHALL PROVIDE THE SUBCONTRACTOR WITH RESEARCH SCALE VIRAL STOCKS FOR FORMULATION STUDIES. CONTRACTOR SHALL FILORAB1 DEVELOPMENT MATERIAL IS AVAILABLE FOR FORMULATION DEVELOPMENT AND NHP STUDIES. CONTRACTOR SHALL ENSURE FILORAB2 DEVELOPMENT MATERIAL IS AVAILABLE FOR FORMULATION DEVELOPMENT AND NHP STUDIES. CONTRACTOR SHALL ENSURE FILORAB3 DEVELOPMENT MATERIAL IS AVAILABLE FOR FORMULATION DEVELOPMENT AND NHP STUDIES. CONTRACTOR SHALL ENSURE LASSARAB DEVELOPMENT MATERIAL IS AVAILABLE FOR FORMULATION DEVELOPMENT AND NHP STUDIES. PREPARATION OF SEED LOT MATERIALS. CONTRACTOR SHALL PROVIDE THE MASTER CELL BANK FOR VERO CELLS. MASTER VIRUS BANKS FOR FILORAB 1 � 3 HAVE ALREADY BEEN PREPARED. CONTRACTOR SHALL PREPARE A MASTER VIRUS BANK FOR LASSARAB (BY RESCUE OF THE CDNA CLONE) UNDER GMP. CONTRACTOR SHALL ENSURE THAT THE LASSARAB BANK WILL BE PRODUCED. CONTRACTOR SHALL COMMENCE PROJECT IMPLEMENTATION CONTRACTOR SHALL PREPARE STARTING MATERIALS AND SEED BANKS. PREPARATION OF NON-GMP LOT OF GLA-SE. CONTRACTOR SHALL PROVIDE GLA SALT AND SHALL PRODUCE AN ENGINEERING LOT OF GLA-SE. CONTRACTOR SHALL ENSURE THAT GLA-SE WILL BE PREPARED FOR PIVOTAL NHP IMMUNOGENICITY AND CHALLENGE STUDIES AND PIVOTAL GLP TOXICOLOGY STUDY. CONTRACTOR SHALL CONDUCT BULK GLA SALT PRODUCT”
• UNIVERSITY OF MARYLAND

  UEI LTJPSDJXL2K5 · not in the directory yet

  $2M

  Subcontracted by this company · 1 sub-award · latest Mar 23, 2025

  • National Institutes of Health
  • “SCOPE OF WORK: THE CENTER FOR VACCINE DEVELOPMENT AND GLOBAL HEALTH (CVD) WILL FURNISH THE NECESSARY SCIENTIFIC, CLINICAL, ADMINISTRATIVE AND LABORATORY PERSONNEL, AND THE MATERIALS, EQUIPMENT, AND FACILITIES TO EVALUATE A RABIESVECTORED MONOVALENT LASSA FEVER VACCINE IN HUMANS. THIS WORK INCLUDES THE REGULATORY PHASE, THE TRIAL PREPARATORY PHASE, THE EXECUTION PHASE OF THE CLINICAL TRIAL, AND THE ANALYSIS AND RESULTS PHASE. IN THE REGULATORY PHASE, WE WILL COORDINATE ASSEMBLY OF THE PRE-IND BRIEFING PACKAGE, SCHEDULE THE PRE-IND MEETING AND PARTICIPATE IN THE PRE-IND MEETING. WE WILL COORDINATE THE DEVELOPMENT AND FILING OF THE IND PACKAGE, INCLUDING PROVIDING OVERSIGHT OF OUTSIDE VENDORS, AS NEEDED. CVD WILL ACT AS STUDY SPONSOR FOR THE CLINICAL TRIAL. WE WILL DESIGN THE CLINICAL TRIAL PROTOCOL, WITH INPUT FROM ALL PARTNERS. PRIOR TO STARTING THE TRIAL, WE WILL OBTAIN ALL NECESSARY APPROVALS, INCLUDING FROM NIH AND INSTITUTIONAL REVIEW BOARDS; TRAIN STUDY STAFF; DELINEATE ROLES AND TIMELINES; AND ENSURE ADEQUATE FACILITIES AND RESOURCES ARE AVAILABLE TO CONDUCT THE TRIAL ACCORDING TO GOOD CLINICAL TRIAL (GCP) STANDARDS, STANDARD OPERATING PROCEDURES AND OTHER GUIDELINES. WE WILL PERFORM THE CLINICAL TRIAL AS DESIGNED IN THE PROTOCOL, ACCORDING TO ALL ETHICAL, QUALITY AND GCP STANDARDS. THIS WILL INCLUDE STUDY INITIATION; RECRUITMENT, INFORMED CONSENT AND RETENTION OF THE STUDY POPULATION; CONDUCT OF STUDY VISITS PER SCHEDULE; DATABASE CLEANING AND CLOSURE; AND WRITING OF REPORTS AND PUBLICATIONS. WE WILL COMPLY WITH REGULATORY REQUIREMENTS INCLUDING SERIOUS ADVERSE EVENTS (SAES) REPORTING REQUIREMENTS. WE WILL COMMUNICATE AS REQUIRED WITH FUNDERS, AND PARTNERS, AND CONVENE A SAFETY MONITORING COMMITTEE PER THE DETAILS IN THE PROTOCOL. CVD WILL PERFORM ALL DATA RECORDING PROCESSES AND FUNCTIONS, INCLUDING CASE REPORT FORM DESIGN, DATA COLLECTION AND ENTRY, SOURCE DOCUMENTATION. WE WILL ENSURE THAT CLINICAL DATA ARE ACCURATE, COMPLETE AND TIMELY. WE WILL ENSURE THE”

No active exclusion on record (checked Nov 14, 2026).

Agencies generally may not award to excluded parties, and primes may not subcontract with them above the threshold in FAR 52.209-6 (except COTS items) without a compelling reason reported to the contracting officer (FAR 9.405, 9.405-2). Some exclusion types apply only to specific programs: read the record on SAM.gov.

No confirmed match on the Consolidated Screening List (screened Nov 14, 2026).

The list combines Commerce, State and Treasury export-control and sanctions lists. A “no match” result is a name-and-address screen, not an export-compliance determination.